New CAR T strategy highly effective against small cell lung cancer in preclinical study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A new approach to chimeric antigen receptor T-cell therapy has shown great promise against small cell lung cancer in a preclinical study. The findings cover new ground in our understanding of how CAR T can be employed against solid-tumor cancers, and provide support for further studies in cancer patients.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Lauren Averett Byers, professor of thoracic/head & neck medical oncology at the University of Texas MD Anderson Cancer Center, received the 2025 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology. The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer, which have paved the way for personalized treatments, even in the most highly recalcitrant cancers.
Break Through Cancer has launched the PoweRD 2 Cure ALK+ Lung Cancer TeamLab, a collaboration among nine leading cancer research institutions, including Break Through Cancer’s five partner institutions: Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, MIT’s Koch Institute for Integrative Cancer Research, and the University of Texas MD Anderson Cancer Center, as well as newly engaged collaborators from Mass General Brigham, Boston Children’s Hospital, the University of Colorado Cancer Center and Vanderbilt University Medical Center.
Genentech’s phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer, did not reach the primary endpoint of overall survival at the final analysis. The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. The detailed data will be presented at a medical meeting in 2025.
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia who were treated with the novel anti-CD19 chimeric antigen receptor T-cell therapy, obecabtagene autoleucel, experienced high response rates and most did not need a subsequent stem cell transplant, according to results from the phase Ib/II FELIX trial co-led by researchers at the University of Texas MD Anderson Cancer Center.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login